Zoetis Inc - Class A (ZTS) Valuation

From a pure valuation perspective, Zoetis appears deeply undervalued. The GoodMoat Target of $207.59 suggests an intrinsic value more than 75% above the current price of $116.71. This implies a margin of safety of approximately 44%, which, according to the framework's bands, qualifies as 'Deeply Undervalued' (>40%). The forward P/E of 19.2x is also reasonable, sitting below the sector average for profitable healthcare companies and not demanding given the company's high profitability metrics like an 80.2% ROE and 37.8% operating margin. The 4.4% Free Cash Flow Yield is attractive and supports the dividend. However, a value investor must reconcile this cheap price with the business fundamentals. The 3.0% year-over-year revenue growth is low, and the Debt/Equity ratio of 2.77 is high, indicating significant financial leverage. While the valuation is highly favourable, the framework's Step 1 gate requires a strong moat and quality profile to proceed. The low growth and high debt are potential quality concerns that an investor must weigh against the company's dominant market position and exceptional profitability to determine if the business itself qualifies for investment before the price is considered. Analysis based on data as of 2024-07-22.